Off-label Use of Dupilumab for Pediatric Patients with Atopic Dermatitis: A Multicenter Retrospective Review.

Sean Igelman,Anastasia O Kurta,Umar Sheikh, Ashley McWilliams,Eric Armbrecht,Stephanie R Jackson Cullison, Douglas W Kress,Anna Smith,Leslie Castelo-Soccio,James Treat, William D Boothe,Lucia Z Diaz,Moise L Levy, Avni Patel,Lara Wine Lee, M Carmen Fraile-Alonso,Richard J Antaya,Sonal Shah,Nicole Kittler,Lisa Arkin,Elaine Siegfried

Journal of the American Academy of Dermatology（2020）

引用 52|浏览25

暂无评分

摘要

Access to dupilumab was achievable for the majority of children, after a mean 9-week delay due to insurance denial. This review supports dupilumab response and tolerability in children. Optimal dosing for patients under age 12 has not been defined. Availability in two different concentrations is an important safety issue.

查看译文

关键词

atopic dermatitis,dupilumab access,dupilumab dosing,eczema,pediatric

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要